Research programme: therapeutic vaccines - Provecs MedicalAlternative Names: Im01; Im03; Immunalon®
Latest Information Update: 16 Jul 2016
At a glance
- Originator Provecs Medical
- Class Vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Infections; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Infections in Germany (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Germany (Intratumoural, Injection)
- 31 Dec 2010 Early research in Infections in Germany (Parenteral)